Retrieve available abstracts of 10 articles: HTML format
Single Articles
May 2025
SUN Z, Yi Z, Wei C, Wang W, et al LILRB3 genetic variation is associated with kidney transplant failure in African
American recipients.
Nat Med. 2025;31:1677-1687. PubMedAbstract available
January 2025
TEERAWATTANANON Y, Chavarina KK, Phannajit J, Sutawong J, et al The Access to Dialysis in Low- and Middle-Income Countries Commission: lessons
for universal health coverage.
Nat Med. 2025;31:19-21. PubMed
October 2024
VADUGANATHAN M, Filippatos G, Claggett BL, Desai AS, et al Author Correction: Finerenone in heart failure and chronic kidney disease with
type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and
mortality outcomes.
Nat Med. 2024 Oct 28. doi: 10.1038/s41591-024-03372. PubMed
APPERLOO EM, Gorriz JL, Soler MJ, Cigarran Guldris S, et al Semaglutide in patients with overweight or obesity and chronic kidney disease
without diabetes: a randomized double-blind placebo-controlled clinical trial.
Nat Med. 2024 Oct 25. doi: 10.1038/s41591-024-03327. PubMedAbstract available
September 2024
HOBBS FDR, McManus RJ, Taylor CJ, Jones NR, et al Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic
kidney disease: a randomized controlled trial.
Nat Med. 2024 Sep 30. doi: 10.1038/s41591-024-03263. PubMedAbstract available
VADUGANATHAN M, Filippatos G, Claggett BL, Desai AS, et al Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the
FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes.
Nat Med. 2024 Sep 1. doi: 10.1038/s41591-024-03264. PubMedAbstract available
July 2024
CHERTOW GM, Chang AM, Felker GM, Heise M, et al Author Correction: IL-6 inhibition with clazakizumab in patients receiving
maintenance dialysis: a randomized phase 2b trial.
Nat Med. 2024 Jul 3. doi: 10.1038/s41591-024-03156. PubMed
June 2024
MANN JFE, Rossing P, Bakris G, Belmar N, et al Effects of semaglutide with and without concomitant SGLT2 inhibitor use in
participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
Nat Med. 2024 Jun 24. doi: 10.1038/s41591-024-03133. PubMedAbstract available
May 2024
CHERTOW GM, Chang AM, Felker GM, Heise M, et al IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a
randomized phase 2b trial.
Nat Med. 2024 May 25. doi: 10.1038/s41591-024-03043. PubMedAbstract available
KONDO T, Jhund PS, Gasparyan SB, Yang M, et al A hierarchical kidney outcome using win statistics in patients with heart failure
from the DAPA-HF and DELIVER trials.
Nat Med. 2024;30:1432-1439. PubMedAbstract available